Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Since joining Driscoll in 2024, he has expanded pediatric urology offerings, including new technologies that enable faster ...

Oncology Media Relations   Oncology_media_relations@its.jnj.com     Investor contact: Jess Margevich investor-relations@its.jnj.com ...

Well, enGene is a unique company with unique technology at actually a really unique time, right? So our technology is called the DDX pl ...

It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

A surgeon in London has successfully removed a patient’s prostate in Gibraltar using a ...

LONDON, Feb 23 (Reuters) - British corporate sectors that once drove national productivity growth have fallen behind the global leaders and the government's strategy for improvement must be hard-edged ...

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Enrollment has been completed in Study II and Theralase® expects to ...

Introduction: Conservative or upfront radical management for high- and very high-risk non-muscle-invasive bladder cancer continues to be debated, particularly for cases with adverse pathological ...

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to ...

Limb-lengthening can add inches to a person’s stature. But its risks have made it controversial. Credit... Supported by By Isabella Kwai Photographs by Matthew Leifheit Isabella Kwai spoke to ...

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. -- Lt. Col. Ronald “RJ” Caras, a urologist at Madigan Army Medical Center, has been named the American Urological Association’s “Young ...